Skip to content

DEVLIES PHARMA

Active Private limited companyfounded 2005active for 20 yearsMoeskroensesteenweg 81, 8511 KortrijkKBO/BCE: BE 0877.804.765

Lifetime

19 annual accounts with figures on one time axis
peak of €186,265 in 2010
€126,931▼ 16.4%
lowest -€21,328 in 2018
-€13,894▼ €19,427
peak of €201,590 in 2009
€149,857▼ 8.5%
€525,785▼ 5.1%
peak of 2 FTE in 2010
0.8 FTEunchanged
Board2 names since 2010
2 directors and 1 other
Documentsfilings and deeds
15-12-202547 days before the deadline
2025abbreviated format
Gross margin from €151,895 to €126,931Loss of €13,894

Key points

from the 2025 annual accounts

Debts

€525,785 78% of the balance sheet
Financial debts 51%Suppliers 24%Taxes and wages 1%Other 24%

Of this, €330,285 falls due within a year.

Filings

19 annual accounts since 2007
deadline2010201520202025

The last five annual accounts were filed 32 to 47 days before the end of the period.

Position in the sector

-€13,894

Lower net result than 82% of companies in retail trade. The sector median is €37,977, over 13,310 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 2,454 companies had the same profile as DEVLIES PHARMA has now. Each dot stands for 7 companies, two years later.

93.2%
were still trading
5.1%
stopped another way
1.6%
went bankrupt
  • Micro
  • 20 years or older
  • solvency 10 to 30%
  • a small loss

Another 0.2% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,894 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.4% 0.5%
3 0.6% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.4% 1.6%
7 1.7% 1.8%
8 1.9% 2.0%
9 3.1% 3.3%
10 5.9% 6.4%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 2,454 companies, not a prediction for DEVLIES PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, , since 13-04-2022
Director, , since 02-12-2022
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0877804765
Environmental permit granted Change of use · decided by Kortrijk
1 director appointed, 1 resignation resigns · . appointed · acts as permanent representative · General meeting of 02-12-2022 · Gazette deed
Company renamed from Apotheek Leys to Devlies Pharma changes role from sole manager to director · . resigns as manager · DP appointed as director · General meeting of 13-04-2022 · Gazette deed
All 36 events

Comparable companies

same main activity, similar in size and age
Company
DEVLIES PHARMA Kortrijk €675,641 €126,931 22.2% 0.8
FRANCART-DELFOSSE PHARMA Courcelles €645,104 €138,346 35.9% 0.7
DEMAPHARMA Ottignies-Louvain-la-Neuve €659,253 €122,780 58.5% 1
APOTHEEK AMPE Kortrijk €558,220 €152,019 34.8% 1
Oostpharma Assenede €627,051 €146,732 38.8% 1
PHARMACIE MEURENS Oupeye €539,712 €148,252 22.2% 0.8
PHARMACIE PATURIAUX Colfontaine €731,921 €127,764 11.3% 0.5

These companies have the same main activity as DEVLIES PHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €540,000 and €732,000, founded between 2003 and 2006.

Official details

Source: KBO
Status
Active since 09-12-2005Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730and 4 others
Joint committee
313Pharmacies and pricing offices · annual accounts 30-06-2023
Establishment unit
2.150.566.2148511 Kortrijk, since 01-01-2006
Financial year end
30 June
Peppol
Reachable since 29-12-2025
Company details

Annual accounts to 30-06-2025

≈ €600,000estimated
€675,641▼ 5.8%
Employeeson 30-06-2025
1=
Filing
Filed on 15-12-2025, 47 days before the end of the filing period
Financials

Insights on DEVLIES PHARMA

DEVLIES PHARMA files the abbreviated format. That format states no turnover. The gross margin fell from €183,790 in 2007 to €126,931 in 2025.

The balance sheet grew most in 2015 through fixed assets, financed with long-term debt.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about DEVLIES PHARMA

What is the company number of DEVLIES PHARMA?
The company number of DEVLIES PHARMA is 0877.804.765. The VAT number is the same number with BE in front: BE 0877.804.765.
Where is DEVLIES PHARMA based?
The registered office is at Moeskroensesteenweg 81, 8511 Kortrijk.Company details
What does DEVLIES PHARMA do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of DEVLIES PHARMA?
DEVLIES PHARMA is a private limited company (BV).
When was DEVLIES PHARMA founded?
DEVLIES PHARMA was founded on 09-12-2005.
Is DEVLIES PHARMA still active?
Yes, DEVLIES PHARMA is an active enterprise in the KBO register.
How many employees does DEVLIES PHARMA have?
DEVLIES PHARMA had an average of 0.8 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
Which joint committee does DEVLIES PHARMA fall under?
In its 30-06-2023 annual accounts, DEVLIES PHARMA states joint committee 313 (Pharmacies and pricing offices).
What is the turnover of DEVLIES PHARMA?
The turnover in financial year 2025 is about €600,000. This figure is estimated from the gross margin of €126,931 and 43 comparable companies (NACE 477). It probably lies between €390,000 and €1.3m.
Is DEVLIES PHARMA profitable?
In financial year 2025, DEVLIES PHARMA made a loss of €13,894.
Where can I find the annual accounts of DEVLIES PHARMA?
DEVLIES PHARMA filed 19 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of DEVLIES PHARMA due?
DEVLIES PHARMA must file the annual accounts for financial year 2026 by 31-01-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.